ZSTK3341
ZSTK3341 is an aryl hydrocarbon receptor (AhR) and cytochrome P450 1A1 (CYP1A1) dependent cell growth inhibitor. ZSTK3341 exhibits growth inhibitory activity against cancer cells. ZSTK3341 can be used in the research of triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C20H14FN5
- Molecular Weight:343.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CYP1A1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-468 | IC50 |
2.89 nM
|
Antiproliferative activity against parental MDA-MB-468 (MM468) triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Cell Counting Kit-8 assay.
Antiproliferative activity against parental MDA-MB-468 (MM468) triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Cell Counting Kit-8 assay.
|
41628058 |
ZSTK3341 (0-10000 nM; 72 h) potently inhibits the growth of parental MDA-MB-468, Doxorubicin (HY-15142A)-resistant MDA-MB-468/AR, and Paclitaxel (HY-B0015)-resistant MDA-MB-468/PR cells, with IC50 values of 2.89, 9.18, and 3.81 nM, respectively[1].
ZSTK3341 (0.1-10000 nM; 72 h) inhibits the growth of wild-type and CYP1A1-knockout T47D breast cancer cells in a dose-dependent manner, but its activity is significantly reduced in AhR-knockout T47D breast cancer cells[1].
ZSTK3341 (0.6-10 nM) induces CYP1A1/CYP1B1 activity in wild-type T47D breast cancer cells, while this activity is significantly reduced in CYP1A1-knockout T47D breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468, MDA-MB-468/AR, MDA-MB-468/PR cells
-
Concentration:0.01, 0.1, 1, 10, 100, 1000, 10000 nM
-
Incubation Time:72 h
-
Result:Potently inhibited the growth of parental MM468 TNBC cells with an IC50 of 2.89 nM.
Inhibited the growth of Doxorubicin-resistant MM468/AR TNBC cells with an IC50 of 9.18 nM, maintaining efficacy comparable to its activity in parental cells.
Inhibited the growth of Paclitaxel-resistant MM468/PR TNBC cells with an IC50 of 3.81 nM, maintaining efficacy comparable to its activity in parental cells.
-
Cell Line:wild-type T47D breast cancer cells, AhR-knockout T47D breast cancer cells, CYP1A1-knockout T47D breast cancer cells
-
Concentration:0.01, 0.1, 1, 10, 100, 1000, 10000 nM
-
Incubation Time:72 h
-
Result:Inhibited the growth of wild-type and CYP1A1-knockout T47D cells in a dose-dependent manner.
Showed significantly reduced growth inhibition activity in AhR-knockout T47D cells across all tested concentrations.
Chemical Information
-
Molecular Weight 343.36
-
Formula C20H14FN5
-
SMILES
FC(C=C1)=CC=C1C2=NC(N3C(C=CC=C4)=C4N=C3)=NC5=C2C=CN5C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ZSTK3341 Related Classifications
HY-188098 Related Classifications
Powered by Bioz
- ZSTK3341
- ZSTK 3341
- ZSTK-3341
- Aryl Hydrocarbon Receptor
- Cytochrome P450
- aryl hydrocarbon receptor
- AhR-knockout cells
- MDA-MB-468 TNBC cells
- CYP1B1
- pan-caspase inhibitor
- triple-negative breast cancer cells
- T47D breast cancer cells
- cytochrome P450 1A1
- paclitaxel-resistant MDA-MB-468/PR TNBC cells
- adriamycin-resistant MDA-MB-468/AR TNBC cells
- Inhibitor
- inhibitor
- inhibit